Logo

Gilead Collaborates with Goldfinch Bio to Develop and Commercialize Therapies for Kidney Disorders

Share this

Gilead Collaborates with Goldfinch Bio to Develop and Commercialize Therapies for Kidney Disorders

Shots:

  • Goldfinch to receive $55M upfront including $5M equity investment- $1.95B milestones for the first five opted programs and royalties on sales of products- retaining the option for lead development & co-promotion of optioned products targeting kidney disease plus equal development cost/profit share in the US 
  • Gilead to get an exclusive option to license WW rights for the therapies- developed by Goldfinch’s Kidney Genome Atlas (KGA) and is responsible for development & commercialization of optioned products. Gilead to provide the $54M fund to Goldfinch KGA’s program for DKD
  • Goldfinch’s Kidney Genome Atlas program enables the discovery of genetic variants associated with kidney disease and will expand it in orphan kidney diseases including DKD

Ref: Gilead | Image: Goldfinch

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions